CSIMarket
 


Denali Therapeutics Inc   (DNLI)
Other Ticker:  
 
 

DNLI's Capital Expenditures Growth by Quarter and Year

Denali Therapeutics Inc 's Capital Expenditures results by quarter and year




DNLI Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 2.24 4.85 3.05 1.20
III Quarter September 2.07 6.05 1.88 0.71
II Quarter June 5.85 2.89 0.77 0.32
I Quarter March 2.79 4.04 2.80 0.88
FY   12.95 17.83 8.50 3.11



DNLI Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Denali Therapeutics Inc reported drop in Capital Expenditures in the fourth quarter 2023 by -53.92% to $ 2.24 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Denali Therapeutics Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 162.67%.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 23 other companies have achieved higher Capital Expenditures growth. While Denali Therapeutics Inc ' s Capital Expenditures meltdown of -53.92% ranks overall at the positon no. 1686 in the fourth quarter 2023.




DNLI Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -53.92 % 59.02 % 154.17 % -56.68 %
III Quarter September -65.79 % 221.81 % 164.79 % -75.09 %
II Quarter June 102.42 % 275.32 % 140.63 % -96.88 %
I Quarter March -30.94 % 44.29 % 218.18 % -56.65 %
FY   -27.4 % 109.76 % 173.31 % -82.65 %

Financial Statements
Denali Therapeutics Inc 's fourth quarter 2023 Capital Expenditures $ 2.24 millions DNLI's Income Statement
Denali Therapeutics Inc 's fourth quarter 2022 Capital Expenditures $ 4.85 millions Quarterly DNLI's Income Statement
New: More DNLI's historic Capital Expenditures Growth >>


DNLI Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 7.97 % -19.83 % 62.23 % 69.01 %
III Quarter September -64.62 % 109.34 % 144.16 % 121.88 %
II Quarter June 109.68 % -28.47 % -72.5 % -63.64 %
I Quarter March -42.47 % 32.46 % 133.33 % -68.23 %
FY (Year on Year)   -27.4 % 109.76 % 173.31 % -82.65 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #24
Healthcare Sector #224
Overall #1686

Capital Expenditures Y/Y Growth Statistics
High Average Low
1695.63 % 162.67 % -96.93 %
(Jun 30 2019)   (Jun 30 2020)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #24
Healthcare Sector #224
Overall #1686
Capital Expenditures Y/Y Growth Statistics
High Average Low
1695.63 % 162.67 % -96.93 %
(Jun 30 2019)   (Jun 30 2020)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Denali Therapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
406.46 % 40.42 % -72.43 %
(Jun 30 2019)  


DNLI's IV. Quarter Q/Q Capital Expenditures Comment
Denali Therapeutics Inc achieved in the IV. Quarter 2023 below company average Capital Expenditures increase of 7.97% quarter on quarter, to $ 2.24 millions.

IV. Quarter 2023 results were paradoxical, even if below the average, yet it presents a quite acceleration measured to the -19.83% in the IV. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Denali Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 647.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #84
Overall #647
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #84
Overall #647
Capital Expenditures Q/Q Growth Statistics
High Average Low
406.46 % 40.42 % -72.43 %
(Jun 30 2019)  


DNLI's IV. Quarter Q/Q Capital Expenditures Comment
Denali Therapeutics Inc achieved in the IV. Quarter 2023 below company average Capital Expenditures increase of 7.97% quarter on quarter, to $ 2.24 millions.

Albeit the IV. Quarter 2023 Denali Therapeutics Inc 's performance was lower than the average of 40.42 %, that has been still promising news, as the current improvement, transcends the -19.83% Capital Expenditures rise in the IV. Quarter 2022

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Denali Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 647.


Denali Therapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 12.94 $ 15.55 $ 19.54 $ 16.58 $ 17.83
Y / Y Capital Expenditures Growth (TTM) -27.44 % -3.02 % 64.69 % 70.19 % 109.8 %
Year on Year Capital Expenditures Growth Overall Ranking # 61 # 145 # 165 # 326 # 140
Seqeuential Capital Expenditures Change (TTM) -16.81 % -20.38 % 17.84 % -7.04 % 11.2 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 489 # 566 # 758 # 1116 # 784




Cumulative Capital Expenditures growth Comment
Denali Therapeutics Inc 's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -27.44% year on year, at Dec 31 2023 compare to the -3.02% decrease at Sep 30 2023. If the Denali Therapeutics Inc 's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $13 millions.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 61, from total ranking in previous quarter at 145.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
428.12 %
70.73 %
-82.73 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 9
Overall # 61

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
428.12 %
70.73 %
-82.73 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 52
S&P 500 # 489
Cumulative Capital Expenditures growth Comment
Denali Therapeutics Inc 's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -27.44% year on year, at Dec 31 2023 compare to the -3.02% decrease at Sep 30 2023. If the Denali Therapeutics Inc 's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $13 millions.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 61, from total ranking in previous quarter at 145.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
428.12 %
70.73 %
-82.73 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 9
Overall # 61

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
428.12 %
70.73 %
-82.73 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 52
S&P 500 # 489




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
DNLI's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for DNLI's Competitors
Capital Expenditures Growth for Denali Therapeutics Inc 's Suppliers
Capital Expenditures Growth for DNLI's Customers

You may also want to know
DNLI's Annual Growth Rates DNLI's Profitability Ratios DNLI's Asset Turnover Ratio DNLI's Dividend Growth
DNLI's Roe DNLI's Valuation Ratios DNLI's Financial Strength Ratios DNLI's Dividend Payout Ratio
DNLI's Roa DNLI's Inventory Turnover Ratio DNLI's Growth Rates DNLI's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Sunshine Biopharma Inc -0.43%$ -0.431 millions
Infusystem Holdings Inc -0.73%$ -0.730 millions
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Precipio inc -5.77%$ -5.769 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Biolinerx Ltd -11.45%$ -11.450 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Cardiol Therapeutics inc -13.92%$ -13.917 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com